By combining AI, clinical testing and computer analysis of vast amounts of biomedical knowledge and electronic health records, researchers at Case Western Reserve University have found...
Awakn Life Sciences has signed its first Licensing Partnership agreement in Europe with a healthcare consortium.
Researchers from The University of Queensland have discovered the active compound from Hericium erinaceus – otherwise known as Lion’s mane – that boosts nerve growth and...
Filament Health has been issued two new patents for the extraction and standardisation of natural psilocybin and associated psychedelic compounds.
Psychedelic-assisted therapy company Better U has created a Military Liaison Officer position to help expand access for veterans.
Awakn has entered into a new partnership agreement with Nushama, one of New York’s leading ketamine-assisted therapy centres.
Enosis, OVID and the MIND Foundation are launching an in-clinic pilot offering of psychedelic-augmented psychotherapy that will leverage Virtual Reality (VR) technology.
Verywell Mind has carried out a survey, revealing that one in three Americans who are currently in therapy are willing to try psychedelics to help with...
Researchers from Inserm, CNRS, Sorbonne University and clinicians from the AP-HP and at Paris Brain Institute identified one of the mechanisms explaining ketamine effect as an...
The clinical trial, carried out by a wholly-owned subsidiary of Creso Pharma Limited, Halucenex Life Sciences Inc.,
